Condition
Bone Marrow Fibrosis
Total Trials
2
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 2 (1)
Trial Status
Active Not Recruiting1
Withdrawn1
Clinical Trials (2)
Showing 2 of 2 trials
NCT03333187Phase 2Active Not RecruitingPrimary
Ruxolitinib vs Allogeneic SCT for Patients With Myelofibrosis According to Donor Availability
NCT04629651Phase 1WithdrawnPrimary
Captopril Use on the Degree of Marrow Fibrosis in Bone Marrow Fibrosis/Myeloproliferative Neoplasms
Showing all 2 trials